Literature DB >> 6571523

Recall of radiation pneumonitis after intrapleural administration of doxorubicin.

A B Hill, S F Tattersall.   

Abstract

A 67-year-old woman developed a malignant pleural effusion 18 months after radical mastectomy and radiotherapy for carcinoma of the breast. After drainage, 30 mg of doxorubicin was instilled into the pleural cavity. Thirty-six hours later, she developed fever, dyspnoea, and erythema in the area of the previous radiotherapy field; patchy intrapulmonary opacities were evident on chest X-ray film. These features resolved over two weeks after treatment with prednisone and frusemide. We believe that this represents a radiation-recall phenomenon.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571523     DOI: 10.5694/j.1326-5377.1983.tb136023.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.

Authors:  Xiao Ding; Wei Ji; Junling Li; Xiangru Zhang; Luhua Wang
Journal:  Radiat Oncol       Date:  2011-03-06       Impact factor: 3.481

Review 2.  Radiation recall with anticancer agents.

Authors:  Howard A Burris; Jane Hurtig
Journal:  Oncologist       Date:  2010-11-02

Review 3.  Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized.

Authors:  Pei-Rung Jan; John Wen-Cheng Chang; Chiao-En Wu
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

Review 4.  Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects.

Authors:  Anup Kainthola; Teena Haritwal; Mrinialini Tiwari; Noopur Gupta; Suhel Parvez; Manisha Tiwari; Hrideysh Prakash; Paban K Agrawala
Journal:  Front Immunol       Date:  2017-05-02       Impact factor: 7.561

5.  Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study.

Authors:  Danijela Vasiljevic; Christoph Arnold; David Neuman; Katharina Fink; Marina Popovscaia; Irma Kvitsaridze; Meinhard Nevinny-Stickel; Markus Glatzer; Peter Lukas; Thomas Seppi
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.